Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 30442501

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2018 Dec
First author
Ladenstein R

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Dec;19(12):1549-1551. doi: 10.1016/S1470-2045(18)30627-2.
    note
    Source null
    related pmid
    30442498
    relationship
    Comment in

Authors and identifiers

  1. name
    Ladenstein R
    type
    Author
  2. name
    Pötschger U
    type
    Author
  3. name
    Valteau-Couanet D
    type
    Author
  4. name
    Luksch R
    type
    Author
  5. name
    Castel V
    type
    Author
  6. name
    Yaniv I
    type
    Author
  7. name
    Laureys G
    type
    Author
  8. name
    Brock P
    type
    Author
  9. name
    Michon JM
    type
    Author
  10. name
    Owens C
    type
    Author
  11. name
    Trahair T
    type
    Author
  12. name
    Chan GCF
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Ladenstein R
    type
    Author
  2. name
    Pötschger U
    type
    Author
  3. name
    Valteau-Couanet D
    type
    Author
  4. name
    Luksch R
    type
    Author
  5. name
    Castel V
    type
    Author
  6. name
    Yaniv I
    type
    Author
  7. name
    Laureys G
    type
    Author
  8. name
    Brock P
    type
    Author
  9. name
    Michon JM
    type
    Author
  10. name
    Owens C
    type
    Author
  11. name
    Trahair T
    type
    Author
  12. name
    Chan GCF
    type
    Author
bibliography ids
  1. nci-bib-ea05f1b367013bd6583ff639
book metadata
content sha256
237b3ccbbd3995c25597ba6731e89988c1147293d9ae9c4006069d9e8d384965
document type
citation
dois
  1. 10.1016/S1470-2045(18)30578-3
electronic publication date
display
2018 Nov 12
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:30442501
immutable id
pubmed:30442501@237b3ccbbd3995c25597ba6731e89988c1147293d9ae9c4006069d9e8d384965
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
12
name
The Lancet. Oncology
nlm unique id
100957246
pages
1617-1629
volume
19
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Dec;19(12):1549-1551. doi: 10.1016/S1470-2045(18)30627-2.
    note
    Source null
    related pmid
    30442498
    relationship
    Comment in
outcomes validated
false
pmid
30442501
provenance
batch id
438b2803888025c6cf56
provider
NCBI PubMed ESummary
record sha256
e8da278fe872dd97f2177d45407fc2eaa481bf4b3f7d18ffa8a69a80f6040765
response sha256
0adf5ff07d3aa03a45feef5e4b7998e2ddea370eb9d1c6aa9134c5fd329767e6
retrieved at
2026-09-09T23:47:36.359220+00:00
publication date
display
2018 Dec
precision
month
year
2018
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/30442501/
title
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.

Preserved source evidence · Not medical advice